Lunai Bioworks Inc. /
Clemann Group, SAS
Lunai Bioworks agrees to buy Alzheimer's drug assets




Source for the buyer and target: Lunai Bioworks Inc.
For the buyer and target.
“Sacramento, CA — March 26, 2026 — Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer’s drug assets from the Clemann Group, SAS or its assignee.”
Published 30 Mar 2026
Open the sourceWhat happened
Lunai Bioworks signed a binding agreement with Clemann Group, SAS to acquire blood-brain barrier delivery technology and related central nervous system Alzheimer's drug assets. The deal is structured as a $20.0 million strategic investment paid in Series B Convertible Preferred Stock. [01]
The closing remains subject to customary conditions, so the transaction is not yet complete. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Lunai Bioworks agrees to buy Alzheimer's drug assets
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly